208771-95-3 Usage
Derivative of benzimidazole
Yes
Explanation
A derivative is a compound that is structurally related to another compound, in this case, benzimidazole. The presence of a carboxamide group and two methyl groups differentiates it from the parent compound.
Explanation
The presence of methyl groups can alter the compound's reactivity, solubility, and interaction with other molecules, which in turn can affect its biological activity and potential applications.
Explanation
As with many chemicals, 1H-Benzimidazole-2-carboxamide,N,4-dimethyl-(9CI) may pose health risks if not handled with care. It is essential to follow safety guidelines and precautions when working with 1H-Benzimidazole-2-carboxamide,N,4-dimethyl-(9CI).
Explanation
The CAS (Chemical Abstracts Service) number is a unique identifier assigned to a specific chemical compound. It helps in the accurate identification and classification of chemicals in databases and scientific literature.
Pharmaceutical industry use
Intermediate in the synthesis of various pharmaceutical drugs
Methyl groups
Two
Chemical and biological properties
Affected by the presence of methyl groups
Health hazards
Potential health hazards if not handled properly
Check Digit Verification of cas no
The CAS Registry Mumber 208771-95-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,8,7,7 and 1 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 208771-95:
(8*2)+(7*0)+(6*8)+(5*7)+(4*7)+(3*1)+(2*9)+(1*5)=153
153 % 10 = 3
So 208771-95-3 is a valid CAS Registry Number.
208771-95-3Relevant academic research and scientific papers
Benzamide derivatives having a vasopressin antagonistic activity
-
, (2008/06/13)
This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I): wherein R1is aryl optionally substituted with lower alkoxy, etc., R2is lower alkyl, etc., R3is hydrogen, etc., A is NH, etc., E is etc., X is —CH═CH—, —CH═N—, or S, and Y is a condensed heterocyclic group, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and to a pharmaceutical composition comprising the same.
